| Size | Price | Stock |
|---|---|---|
| 1mg | $214 | In-stock |
| 5mg | $450 | In-stock |
| 10mg | $800 | In-stock |
| 25mg | $1650 | In-stock |
| 50mg | $2550 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-123941 |
| M.Wt: | 1210.32 |
| Formula: | C63H79N5O19 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL |
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research[1][2].
IC50 & Target:FKBP12F36V[1]
BRD4[1]
PROTAC[1]
In Vitro:The FKBP12 PROTAC dTAG-7 effectively induces heterodimerization of purified CRBN-DDB1 and FKBP12F36V proteins in cell-free AlphaScreen assays[1].
The FKBP12 PROTAC dTAG-7 (100 nM) induces CRBN-dependent degradation of the FKBP12F36V-Nluc fusion protein in 293FTWT cells, but has no effect on endogenous FKBP12WT or the FKBP12WT-Nluc fusion protein, and shows no activity in CRBN-deficient 293FTCRBN−/− cells[1].
The FKBP12 PROTAC dTAG-7 (50 nM) efficiently degrades a variety of FKBP12F36V fusion proteins (FKBP12F36V-KRASG12V, FKBP12F36V-EZH2, HDAC1-FKBP12F36V, MYC-FKBP12F36V, PLK1-FKBP12F36V, BRD4 (short)-FKBP12F36V) in MV4;11 cells, and degrades the endogenously tagged FKBP12F36V-BRD4 fusion protein in homozygous knock-in 293T cells[1].
The FKBP12 PROTAC dTAG-7 (0.01-5 μM; 18 h) induces proteasome-dependent, concentration- and time-dependent degradation of GFP-S8L-F12 in mouse macrophage BMC-2 cells[2].
The FKBP12 PROTAC dTAG-7 (0.015-5 μM; 18 h) specifically reduces GFP-specific fluorescence in mouse macrophage BMC-2 cells in a concentration-dependent manner (indicating degradation of mature GFP-S8L-F12), and its effect is fully reversible within 8 h after compound washout[2].
The FKBP12 PROTAC dTAG-7 (1 μM; 0-24 h) induces antigen-specific, FKBP12-dependent enhancement of H-2Kb/S8L MHC class I presentation in mouse macrophage BMC-2 cells, with the peak of presentation observed at 2 h after treatment with 1 μM dTAG-7[2].
The FKBP12 PROTAC dTAG-7 (1 μM; 0-30 h) induces rapid degradation of GFP-S8L-F12 and enhances the presentation of H-2Kb/S8L class I MHC molecules in mouse dendritic cell line DC2.4 and mouse fibrosarcoma cell line MC57G[2].
The FKBP12 PROTAC dTAG-7 (1 μM; 2-6 h) enhances the presentation of H-2Kb/S8L class I MHC molecules in GFP-S8L-F12-expressing mouse macrophage BMC-2 cells and mouse fibrosarcoma MC57G cells[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.